Table 3

Association between expression of SHH signalling proteins and clinicopathological variables

Variables (p value*)	SHH	GLI-1	GLI-2	GLI-3	ABCG2
Age at diagnosis (<2 years)	0.720	0.120	0.032	0.537	0.342
Age at enucleation (<2 years)	0.536	0.029	0.127	0.478	0.329
Sex	0.231	0.351	0.048	0.037	0.223
Bilateral tumours	0.460	0.004	0.014	0.388	0.623
International RB stage	0.001	0.581	0.446	0.240	0.240
Pathological tumour stage	0.029	0.541	0.264	0.024	0.748
Optic nerve invasion	0.004	0.786	0.634	0.163	0.509
Choroidal invasion	0.023	0.258	0.140	0.235	0.186
Extraocular invasion	0.036	0.683	0.541	0.091	0.503
Nodal or distant metastasis	0.001	0.581	0.446	0.240	0.240
Differentiated tumour	0.491	0.016	0.043	0.494	0.024
Preop. chemoradiotherapy	0.140	0.775	0.676	0.324	0.446
Preop. local/proton therapy	0.021	0.663	0.614	0.530	0.530
Postop. chemoradiotherapy	0.047	0.928	0.490	0.180	0.360

*Association was compared with Pearson's χ² test or likelihood ratio test for trend.
ABCG2, ABC binding cassette G2; GLI, glioma-associated oncogene homologue; Postop, postoperative; Preop, preoperative; RB, retinoblastoma; SHH, Sonic hedgehog.